Psychopharmacology & Clinical Practice: Helping or Hurting?
|
|
- George Baker
- 5 years ago
- Views:
Transcription
1 American Psychiatric Nurses Association VII Clinical Psychopharmacology Institute Reston, Virginia June 27, 2009 Psychopharmacology & Clinical Practice: Helping or Hurting? Ross J. Baldessarini, M.D. Professor of Psychiatry & Neuroscience Harvard Medical School Disclosures 2009 Dr. Baldessarini Has been a consultant to, or collaborated in research with: Alkermes, AstraZeneca, Auritec, Biotrofix, IFI, Janssen, JDS- Noven, Leupold, Lilly, Merck, NeuroHealing, Novartis, Pfizer & Solvay Corporations, and holds several unlicensed patents for novel treatments of medical illnesses, but has no speakers panel or equity relationships with industrial organizations Needs & Markets: Psychotropics Illness: Lifetime %-Prevalence a Illness Costs ($B/year) b Substance abuse 27% Mental illness+dementia $28B Anxiety disorders 25% Cardiovascular $17B Major Depression+Dysthymia 24% CNS injuries $12B Antisocial personality 3.5% Cancers $11B Bipolar I disorder 1.6% Mood disorders $10B Schizophrenia & related psychoses 0.7% HIV-AIDS $7.2B 2 Diag noses 27% Arthritis $4.2B Professionally treated 42% Schizophrenia $3.6B Market Share (Income-%) c Psychotropics 8.3% Cancer 6.6% Anticholesterol 4.7% Diabetes 3.8% Proton inhibitors 3.7% Antihypertensive 3.2% Analgesics 3.0% Refs.: [a] Kessler et al. Arch Gen Psychiatry 1994:51:8 19; [b] Greenberg et al. J Clin Psychiatry 1993;54: ; [c] Cowan & IMS Inc (world market = $724.5B; CNS = antidepressant, antipsychotic, anticonvulsant). 1
2 Common Psychotropic Drugs: Generic Brand Names Antidepressants Antipsychotics Mood-Stabilizers Amitriptyline Elavil Aripiprazole Abilify Carbamazepine Tegretol Bupropion Wellbutrin Chlorpromazine Thorazine Divalproex Depakote Citalopram Celexa Clozapine Clozaril Oxcarbazepine Trileptal S-Citalopram Lexapro Fluphenazine Prolixin Lamotrigine Lamictal Clomipramine Anafranil Haloperidol Haldol Lithium Lithobid Desipramine Norpramin Iloperidone Fanapt Desvenlafaxine Pristiq Loxapine Loxitane Mesoridazine Serentil Olanzapine Zyprexa Doxepin Sinequan Paliperidone Invega Duloxetine Cymbalta Perphenazine Trilafon Fluoxetine Prozac Quetiapine Seroquel Fluvoxamine Luvox Risperidone Risperdal Imipramine Tofranil Thiothixene Navane Mirtazapine Remeron Thioridazine Mellaril Nortriptyline Pamelor Trifluoperazine Stelazine Paroxetine Paxil Ziprasidone Geodon Sertraline Zoloft Venlafaxine Effexor [Imipramine, iproniazid, chlorpromazine, clozapine, haloperidol, lithium & c hlordiazepoxide were available by 1960, or 1 agent fr om each class currently in use] Serendipity in psychopharmacology Amphetamines via ephedrine from ma-huang Chlorpromazine antihistaminic preoperative sedative Reserpine Vedic remedy: snakebite & madness Imipramine putative antipsychotic Iproniazid an exciting anti-tb treatment Chlordiazepoxide possibly sedative muscle-relaxant Haloperidol non-analgesic meperidine analog Clozapine surprising imipramine analog Lithium carbonate not so good for gout Fluoxetine antidepressant, but what else? Valproic acid a non-inert solvent Carbamazepine not just another anticonvulsant Buspirone early "atypical antipsychotic" Evolution of modern psychopharmacology Š1950s Long use of sedatives (antihistamines, barbiturates/nonbarbiturates, bromides, cannabis, chloral, ethanol, opiates, Rauwolfia, nonbarbiturates), stimulants (amphetamines), antiparesis agents (mercurials, penicillin), physical methods (baths, restraints, insulin, ECT, leucotomy) 1960s Slow acceptance vs. psychotherapy; commercial potential realized; regulatory proofs become standard (phases I, II, III, post-marketing; patents ca. 17 yrs, time to market: yrs); standardized RCT designs, scales & statistics; proliferation of structural homologs, some behavioral-functional analogs; rise of monoamine theories of pharmacodynamics & primitive pathophysiology; strong repetition-compulsion 1970s Molecular-screening; highly pharmacocentric pathophysiology; drugs-syndromes crosspromote; emergence of new diagnoses 1980 Pharmacocentric & third-party oriented DSM-III; proliferation to 3 00 Dxs; a few novel but not better agents emerge (SRIs, atypicals, buspirone); automatic synthesis & pharmacology 1990s Decade of the brain ; genetics, imaging; new molecular targets; BIG business ( $1 B/yr/drug); some interest in effectiveness vs. efficacy; adverse effects unavoidable Š2000s Hope for evidence-based psychiatry; heavy reliance on RCTs & meta-analysis; growing concern re. trial methods; attempts at Rx-algorithms but pernicious dumbing-down; reemergence of non-drug treatments; missed opportunities (pediatrics, geriatrics, dementia, mortality); empirical-descriptive tradition will not die (no etiology/pathophysiology) 2
3 Official Psychiatric Diagnoses in DSM Number of Diagnoses /1952 II/1968 III/1980 III-R/1987 IV/1994 Editions of DSM (APA) Pharmacocentric Cycle of Biopsychiatry Examples: Pharmaco- "Patho- Treatment Diagnosis dynamics physiology" Haloperidol Schizoph renia Anti-DA DA-excess Lithium Bipolar disorder Anti-CA CA-excess Imipramine Major depression Pro-NE NE-deficiency Alprazolam Panic disorder Pro-GABA GABA-deficiency? Fluoxetine OCD Pro-5-HT 5-HT-deficiency? Therapeutic Choices Ease of use, tolerability & initially perceived safety. Overinterpretion of nonspecific clinical & pharmacological terms & weak research data. Technical displacing psychosocial approaches (manifestation of allopathic compulsion ). Impact of marketing, novelty, fads & personal or local experience; avoid familiar limitations & adverse effects. Efforts to make (industry) or save (administrators) money (expensive/newer vs cheap/older drugs). Time-pressure & incentives may compete with clinical imperatives to help patients. 3
4 Therapeutic choice driven by ease or perceived safety: Displacements Anticonvulsants/antipsychotics vs. lithium SRIs vs. TCAs Anything but MAO inhibitors Oxcarbazepine vs. carbamazepine Gabapentin vs. effective mood-stabilizers Oral antipsychotic polytherapy vs. depots Low-dose antipsychotics vs. benzodiazepines or with antidepressants Response to black-box warnings, even if patently irrational (e.g., anticonvulsants or antipsychotics increase suicidal risk) Such choices often dominated by ease without considering cost by clinicians (vs. administrators). Therapeutics driven by over-interpretation of terms Antidepressant could as well be anxiolytic. Major depression is highly heterogeneous clinically & pharmacologically. Antidepressants overused in bipolar depression despite weak short & long-term efficacy. Antipsychotic could as well be antimanic, but certainly not antischizophrenic. Anticonvulsant-use driven by kindling theory ( unproven in man or bipolar Dx). Exaggerated expectations of all psychotropics. Toward Evidence-based psychiatry Need more complex but representative patients in trials (now mostly highly restricted samples) More head-to-head, randomized trials (conflict of marketing vs. distinction?) Appreciate limitations of meta-analysis of RCTs as a weak basis for EBM (wide variance & regression-to mean) Efficacy vs. effectiveness Address clinical details & subgroup analyses in RCTs Access to individual-level data from RCTs: proprietary but wasted Drug-safety: major regulatory, clinical, & scientific challenge, often post-marketing Trainees need to appreciate these issues & balance traditional clinical aspects vs. technoeconomic forces 4
5 Selective publication: Antidepressant RCT findings Outcome Published p-value Drug > Placebo 37/38 (97.4%) Drug Š Placebo 3/36 (8.3%) <0.001 Difference 11.7x Effect Size Publication [95%CI] Published 0.37 [ ] Not Published 0.15 [ ] <0.005 Difference 2.47x Adapted from Turner EJ et al. New Engl J Med 2008; 358: Of note, data for 27.5% of subjects was not published. Typical Responses to Antidepressants in MDD Adults overall Melancholic-moderate Bipolar depressed Adolescents Melancholic-severe Children Psychotic adults Remission (adults) Placebo (adults) Response (% of Patients) RCTs Comparing Antidepressants vs. Fluoxetine [Drugs; Trials; Ss] [From Cipriani et al. Lancet 2009; 373: ] Mirtazapine (5; 622) S-Citalopram (2;543) Venlafaxine (12; 2446) Sertraline (8; 1352) Citalopram (3; 740) Bupropion (3; 740) Paroxetine (13; 2802) Fluvoxamine (2; 284) Reboxetine (4; 764) Odds Ratio vs. Fluoxetine (95%CI) 5
6 Initial prescriptions for 14,000 Bipolar disorder patients (US) Drugs % of Patients Monotherapies Antidepressants 61.1 Antipsychotics 7.61 Divalproex 6.59 Lithium 2.99 Lamotrigine 1.60 Carbamazepine 0.52 All monotherapy 80.4 Polytherapies Mood-stabilizer + antidepressant 6.27 Antipsychotic + antidepressant Drugs & Miscellaneous 4.09 Mood-stabilizer + antipsychotic 3.12 All Polytherapy 19.6 Total Antidepressants 75.0 From Baldessarini et al. Psychiatr Serv 2007 & Later changes almost always involved adding another drug (polytherapy). Prien et al. 1973a Prien et al. 1973b Quitkin et al Kane et al. 1982a Kane et al. 1982b Kane et al. 1982c Kane et al. 1982d Prien et al. 1984a Prien et al. 1984b Johnstone et al Amsterdam et al Ghaemi et al Meta-analyses: Long-Term Antidepressant Trials in BPD [Ghaemi et al. Acta [Ghaemi Psychiatr et al. Scand 2007] 2008;118: ] Prien et al. 1973a Prien et al. 1973b Quitkin et al Kane et al. 1982a Kane et al. 1982b Kane et al. 1982c Prien et al. 1984a Prien et al. 1984b Ghaemi et al Pooled RR Pooled = 0.73 [ ] Pooled RR Pooled = 1.72 [ ] [NNT = 11] [NNH = 7] Risk Ratio (95% CI) Depression Risk Ratio (95% CI) Mania Odds Ratio ± 95% CI Effects of Modern Antidepressants: "Suicidality" versus Age-Groups FDA Website Nov 2008; 396 RCTs, modern agents, 113,000 Ss Barbui et al. CMAJ 2009; 180: ; 8 cohort studies (on/off SRIs, 200,000 Ss null = < >65 All Ages Age Groups (years) 6
7 Outcomes favoring sponsor s antipsychotic vs. competitor Favored outcome Trials Rate (%)* Sponsor s product 27/ Competitor s product 3/ (*) p<0.001 (sign test); competitors: CLZ, ONZ, RSP (1 trial each). From Heres et al.: Am J Psychiatry 2006; 163: CATIE Study: Adverse Outcomes Discontinued Rxs Added Inefficacy Intolerability Hospitalized [From Lieberman HA et al. N Engl J Med 2005;351: ] 70 % of Subjects ONZ RSP PPZ ZPS QTP Overall Treatments Direct Comparisons of Modern Antipsychotics Drugs (n) Olanzapine (11) Inferior Similar Superior [Adapted from: Leucht et al. Am J Psychiatry 166: ] Clozapine (9) Amisulpride (5) Risperidone (14) Sertindole (2) Ziprasidone (9) Quetiapine (7) Aripirazole (4) % of Comparisons (n) 7
8 Comparisons of Antipsychotic Drugs vs. Placebo [From Leucht S, et al. Mol Psychiatry 2009; 14: ] Drug, RCTs null Risperidone (7) Zotepine (2) Amisulpride (3) Aripiprazole (5) Ziprasidone (2) Olanzapine (4) Haloperidol (10) Quetiapine (5) Sertindole (3) Rate Ratio (Failures vs. Placebo) [95% CI] Controlled Trials in Acute Mania (Drugs; Trials; Ss) [From Yildiz A, Vieta E, Baldessarini RJ; 2009, in press] null Carbamazepine (2; 1399) Olanzapine (5; 1134) Risperidone (3; 823) Haloperidol (4; 1051) Quetiapine (3; 711) Ziprasidone (3; 663) Valproate (4; 824) Asenapine (2; 269) Aripiprazole (6; 1662) Lithium (6; 1199) Odds Ratio vs. Placebo [95% CI] Development Costs & New Products Pharmaceutical Development Costs versus New Product Approvals Costs ($B) New Drugs R&D Costs ($Billions) New Drug Approvals [Sources: Berenson A, NY Times 1/11/05; PhARMA & FDA 2008] Year 8
9 Annual Intitutionalization Rate (per k) Institutionalization Trends: US, Public Mental Hospitals Prisons [From Harcourt BE (U. Chicago). NY Times 01/15/07, p A19] Years Modern psychopharmacology: helping versus hurting Helping Hurting Reduce morbidity Can limit mortality More Rx-options Increase treaters (PCP, RN) Promote medical interest Reduce stigma Stimulate research Make business profit Huge R&D investments Boost employment May support education Oversimplify assessment & Rx Advrse-effect burden Risks shotgun-rx (sans Dx) Diagnoses proliferate Encourages cost-containment Promotes time-pressure Promotes pharmacocentricity Limited clinically & scientfically Novel products/cost declining Risks cyclic boom & bust Risks of corruption feared 9
Medications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationOverview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials
SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the
More informationSteps for Initiating Electroconvulsive Therapy Treatment
Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationPsychopharmacology: Advances & Challenges
Canadian Therapeutics Congress IV Halifax, Nova Scotia May 27 Psychopharmacology: Advances & Challenges Ross J. Baldessarini, M.D. Professor of Psychiatry & Neuroscience Harvard Medical School Disclosures
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationPsychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA
Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationNew Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationDealing with a Mental Health Crisis
Dealing with a Mental Health Crisis Information and Resources for First Responders P... PROFESSIONAL WHAT NAMI DOES NAMI Minnesota is a statewide 501(c)(3) grassroots nonprofit organization dedicated to
More informationMedically Accepted Indications for Pediatric Use of Psychotropic Medications by
Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationTRANSCRANIAL MAGNETIC STIMULATION & BRAIN MUSIC THERAPY
TMS - DEPRESSION HISTORY Date: Patient Name: DOB: How did you hear about TMS? What do you know about TMS? Referring Physician? Name of Practice: Name of Inpatient Treatment for Depression: Name of Inpatient
More informationMO Medicaid Foster Care Drugs FY10-FY14
MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri
More informationHappy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?
Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationSupplement: Tables and Figures
Supplement: Tables and Figures Supplement Table 1. Baseline Characteristics by Study and Efavirenz Assignment Supplement Table 2. Baseline Psychoactive Medications by Efavirenz Assignment* Supplement Table
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationDual Diagnosis: Substance Abuse and Mental Illness
Dual Diagnosis: Substance Abuse and Mental Illness and a review of the major PSYCHIATRIC MEDICINES Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services
More informationMay 22, DAL: DAL SUBJECT: Hot Weather Advisory. Dear Administrator/Operator:
May 22, 2013 DAL: DAL 13-11 SUBJECT: Hot Weather Advisory Dear Administrator/Operator: The New York State Department of Health would like to remind you of our expectations regarding the protection of Adult
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationUSF Health Psychiatry Clinic. New Patient Questionnaire Adult
USF Health Psychiatry Clinic New Patient Questionnaire Adult Please mail or fax the completed forms to the address/fax number on the bottom of this page. Completed forms must be received five (5) days
More informationRichard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
More informationMental Health Medications. National Institute of Mental Health. U.S. Department of HealtH and HUman ServiceS National Institutes of Health
Mental Health Medications National Institute of Mental Health U.S. Department of HealtH and HUman ServiceS National Institutes of Health Contents Mental Health Medications...1 What are psychiatric medications?...1
More informationA Primer on Psychotropic Medications. Michael Flaum, MD
The Iowa Mental Health System and Employment for Individuals with Psychiatric Conditions Iowa Vocational Rehabilitation Services Conference Des Moines, IA, September 18, 2006 A Primer on Psychotropic Medications
More information2015 Update on Psychotropics
2015 Update on Psychotropics Jeffrey T. Apter, M.D. August 2015 Princeton Medical Institute 256 Bunn Drive, Suite 6, Princeton NJ (609) 921-6050 Learning Objectives Upon completion of this session, participants
More informationAAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
AAA Adolescents & Adults with Autism A Study of Family Caregiving add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More information#55 PRESCRIBING AND MONITORING PSYCHI RIC MEDICATIONS
- '_ ADMINISTRA TIVE/FISCAUCLINICAL/PHF POLICY AND PROCEDURES COUNTY OF SANTA BARBARA ALCOHOL, DRUG AND MENTAL HEAL TH SERVICES Section - QUALITY ASSURANCE Effective: 12/1/09 Policy- Director's Approval
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationMental Health Intake Form
Current Symptoms Checklist: (check once for any symptoms present, twice for major symptoms) ( ) ( ) Depressed mood ( ) ( ) Racing thoughts ( ) ( ) Excessive worry ( ) ( ) Unable to enjoy activities ( )
More informationWelcome and thank you for choosing University of Florida Physicians!
DEPARTMENT OF PSYCHIATRY Tuesday, Division of March Child and 14, Adolescent 2017 Psychiatry 8491 NW 39 th Ave. Gainesville, FL 32606 Phone: 352-265-4357 Fax: 352-627-4163 Welcome and thank you for choosing
More informationAnti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.
30-3-2007 Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of. 30-3-2018 C. Psychiatric drugs: controlled trial demonstrated
More informationHOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS
More informationRiding the Waves: Tools for the Management of Bipolar Disorder
Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School
More informationHow did we get here? 1876 Methylene Blue. Insecticide 1935 Du Pont Anthelmintic. Garrett McCann, RPh
Polypharmacy, Adverse Effects, and the Importance of Tapering Medications for People with Intellectual and Developmental Disabilities Garrett McCann, RPh How did we get here? 1876 Methylene Blue Insecticide
More informationUse Brand Only. Preferred Drug Status PRIOR AUTHORIZATION REQUIRED
Generic Drugs Are Over Brand Drugs Unless Specified As Brand ANTIDEPRESSANTS ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANTS MIRTAZAPINE REMERON 30 30 MIRTAZAPINE REMERON SOLTAB 30 30 ISOCARBOXAZID TABLETS
More informationMental Health Intake Form
38600 Van Dyke Ave., Suite 200 Sterling Heights, MI 48313 Phone: (586) 933-5395 Fax: (586) 935-0159 Mental Health Intake Form Please complete all information on this form and bring it to the first visit.
More informationCENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG NAME. Use Brand Only
ACAMPROSATE TABLET DELAYED RELEASE ALPHA-TOCOPHEROL CAPSULES ALPRAZOLAM CONCENTRATE 1 MG/ML ALPRAZOLAM ODT TABLET 0.25MG, 0.5MG, 1MG ALPRAZOLAM ODT TABLET 2MG ALPRAZOLAM SR TABLET 24-HOUR ALPRAZOLAM TABLET
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationMichael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX
A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release
More informationCENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG CLASS
ANTIDEPRESSANTS ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANTS MIRTAZAPINE ODT TABLETS 15 MG REMERON SOL 90 30 MIRTAZAPINE ODT TABLETS 30 MG REMERON SOL 45 30 MIRTAZAPINE ODT TABLETS 45 MG REMERON SOL 30
More informationAdult Initial Assessment / Patient Questionnaire Page 1
Page 1 Patient Name: Date: Age: Date of Birth: / / Please read the following questions and answer to the best of your ability by placing a checkmark in the appropriate boxes or filling in the blank as
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationProfessor David Castle. Ms. Nga Tran. St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065
ARABIIC Professor David Castle Ms. Nga Tran St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 (03) 9288 4147 (03) 9288 4751 Psychiatric Medication Information / Arabic 1 Psychiatric
More informationToo Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities
Too Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities One definition of polypharmacy is using more medications than is medically necessary. However, it can be
More informationMental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Mood Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Mood Prolonged emotional state that influences the person s whole personality and life functioning Adaptive Functions
More informationJohn E. Kraus, M.D., Ph.D.
John E. Kraus, M.D., Ph.D. Chief, Adult Psychiatry, Dorothea Dix Hospital, Raleigh, NC Assistant Professor/Associate Director of Residency Training, Dept. of Psychiatry, UNC Hospitals, Chapel Hill, NC
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationAdverse events of common psychiatric medications: an umbrella review
Adverse events of common psychiatric medications: an umbrella review Katrina Bartellas, 1 Thomas Bajorek 1 Sarah Stockton, 1 Stefan Leucht, 2 Andrea Cipriani, 1 Seena Fazel 1 1 Department of Psychiatry,
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationBefore you try another medication, try asking your DNA
Before you try another medication, try asking your DNA It s not you, it s your genetics If you re having trouble finding a medication that works for you, don t give up hope. Here s the thing we all respond
More informationPatient History Form
Patient History Form Date: / / NAME: Last First Middle Birthdate: / / Age: Sex: F M Please read the following questions and answer to the best of your ability by placing a check mark in the appropriate
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationThe clinical response to the same dose
Making sense of CYP2D6 and CYP1A2 genotype vs phenotype O. Greg Deardorff, PharmD, BCPP, Victoria Jenne, PharmD, MPH, BCPS, and Lauren Leonard, PharmD The clinical response to the same dose of a drug may
More informationmed ed Copyright All rights reserved. No part of this publication can be reproduced without prior written consent of the authors.
med ed Dr. Andrea Murphy, Assistant Professor, School of Nursing, Dalhousie University; Research Associate, Sun Life Financial Chair in Adolescent Mental Health Dr. David Gardner, Associate Professor,
More informationThank you for choosing Pine Rest Christian Mental Health Services. We look forward to providing services to you.
Thank you for choosing Pine Rest Christian Mental Health Services. We look forward to providing services to you. In order to make the most of your first appointment, please come at least 30 minutes prior
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationOBJECTIVES PSYCHOTROPIC MEDICATIONS WHAT IS PSYCHOTROPIC MEDICATION?
PSYCHOTROPIC MEDICATIONS Sally Davies, Ph.D., HSPP Licensed Psychologist OBJECTIVES 1. Identify psychotropic medications and the typical usages 2. Identify effective methods for the practical application
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationAntipsychotics and stroke risk
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Antipsychotics and stroke risk Lockwood G. Taylor, PhD, MPH Division of Epidemiology II Office of Pharmacovigilance
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More information8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation
Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary
More informationWeighty Issues with Psychotropic Use in Adolescents and Young Adults
Weighty Issues with Psychotropic Use in Adolescents and Young Adults Sheila Botts, PharmD, BCPP, FCCP Chief, Clinical Pharmacy Research & Academic Affairs Kristen N. Gardner, PharmD Clinical Pharmacy Specialist
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log
More informationWhat Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationPsychiatric Evaluation Intake Form
Psychiatric Evaluation Intake Form 1. Patient Contact Information Date Patient Name Address Best contact phone number Email address Emergency contact Relationship Phone No Primary Care Physician Tel Fax
More informationHCA BHS Prescribing Guidelines Committee - Approved Medications 2012
Amitriptyline/Perphenazine Triavil MAJOR TRANQUILIZERS Beneficiaries 10/2, 10/4, 25/2, 25/4, 50/4 Aripiprazole Abilify 2mg, 5mg, 10mg, 15mg, 20mg, 30mg Quantity Limit 31 / mo for Asenapine Saphris 5mg,
More informationUsing Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University
Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal Alan Poling, Ph.D., BCBA-D Western Michigan University In a 2010 study of 60,641 children Mandell et al. found that: 56%
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationClinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.
Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationMental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling
Mental Illness Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Moodiness Changing Bodies Narcissism Self-Esteem Ignorant Naïve Insecure Self-Centered Independent Adolescence Disorders Affecting
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationLAGUNA BEHAVIORAL Crown Valley Parkway, Suite 140 Phone: (949) Laguna Niguel, CA Fax: (949)
NEW PATIENT INFORMATION - ADULTS CLIENT INFORMATION Patient s Name: Today s Date: Other Names: Date of Birth: Age: Address: Street Apartment City State ZIP E-mail Address: May we contact you via e-mail
More informationClass: Treatment with Medication:
Class: As we have not finished all the material covering disorders, I wanted to give you and overview of some disorders we have not had a chance to discuss. I feel you are well prepared in different types
More information